January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
February 2016 in “Journal of Allergy and Clinical Immunology” Consider DRIF and perform skin biopsies for persistent papular rashes.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
April 2017 in “Journal of Investigative Dermatology” Certain mutations in the KLHL24 gene cause a skin disorder by breaking down an important skin protein.
1 citations
,
April 2013 in “Journal of Investigative Dermatology” July 2024 in “Journal of Investigative Dermatology” CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.
5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” The gene therapy showed significant wound healing and was safe for treating severe RDEB.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
111 citations
,
February 2017 in “Antiviral research” Researchers found several compounds that could potentially treat Zika virus.
May 2025 in “REVISTA DA ASSOCIAÇÂO DE FARMÁCIAS VIVAS” The serum is effective, safe, and stable for skincare.
8 citations
,
July 2003 in “Journal of the American Geriatrics Society” Venlafaxine may cause paranoid delusions in some patients.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
51 citations
,
December 2006 in “Mammalian Genome”
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
April 2018 in “Journal of Investigative Dermatology” CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
January 2017 in “International journal of surgery and transplantation research” The Covas-Lift is a safe and effective facial rejuvenation method with shorter surgery time and high patient satisfaction.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
14 citations
,
November 2016 in “Lupus” Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
February 2024 in “Reactions weekly”
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
August 2025 in “International Journal of Research in Dermatology” Increasing zinc intake improved skin and hair symptoms in a rare genetic disorder.
2 citations
,
November 2015 in “Journal of Investigative Dermatology” RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.
2 citations
,
January 2017 in “Elsevier eBooks” December 2024 in “International Journal of Scientific Reports” The plant-based hair serum is a promising and safe alternative to minoxidil for hair regrowth.
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
April 2026 in “The Open Biotechnology Journal” Resveratrol shows health benefits but faces challenges in effectiveness and regulation.